Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

Pulmonary embolism (PE) is more common in children than previously thought, according to a study presented at the American ...

For patients with amyotrophic lateral sclerosis (ALS), rapid eye movement (REM) inhibition via receipt of antidepressant ...

Approximately 20% of patients who undergo bronchoscopic lung volume reduction (BLVR) lose the effects of the treatment within ...

STOCKHOLM, SE / ACCESS Newswire / May 22, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, May 22, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

Varying presentations and different means of measuring frailty make it a slippery target for ICU interventions, experts say ...

Remote study conducted at Rutgers and elsewhere finds albuterol-budesonide mix cuts risk for mild cases and may let patients ...